We produce institutional quality equity research on small/midcap healthcare and life sciences companies, making it available to all investors wherever they are based. Our goal is to bring exciting investment ideas to investors, and to assist companies in achieving their objectives.
14
Research Clients
120
Reports published
10k+
Readers in database
.@Evotec maintains its impressive level of growth with revenues up 16% and adjusted EBITDA up 51% in H119. https://t.co/OdTz2cZM9O
Following @HChiMed's H119 results, read our note at https://t.co/WrQb4WeQhK, as the company looks forward to filing two more drugs for approval in China in the coming year.
Following today's announcement that @e_Therapeutics has started working in the field of neurodegeneration with a top 5 biopharma company, which we believe is @Merck; read our note at https://t.co/0lXUbPFA9X
.@MorphoSys confirms filing plans for #MOR208 (#tafasitamab) in r/r #DLBCL; intending to complete EMA MAA submission by mid-2020, and FDA BLA by end-2019 $MOR
.@NexstimOyj's NBT system is now authorized for commercial distribution in Australia for the treatment of #MDD (major depressive disorder)
https://t.co/hxCEFuT3ZW
Abstract titles released for #WCLC19: abstracts will be available on Aug 21st.
$HCM $BGBIO will be presenting data (1/3)
Please sign up here to be added to our distribution database
